Etuvetidigene Autotemcel

Etuvetidigene autotemcel is a gene therapy designed to treat Wiskott-Aldrich Syndrome (WAS), a rare X-linked immunodeficiency caused by mutations in the WAS gene that result in a deficiency of the Wiskott-Aldrich Syndrome protein (WASP). WASP is a key regulator of the actin cytoskeleton in hematopoietic cells, and its absence leads to defects in cell signaling, migration, and immune synapse formation. Etuvetidigene autotemcel consists of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) that are harvested from the patient and genetically modified ex vivo using a lentiviral vector to insert a functional copy of the human WAS complementary DNA (cDNA).

At the molecular level, etuvetidigene autotemcel utilizes a WAS lentiviral vector (LVV) to introduce full-length copies of the human Wiskott-Aldrich Syndrome (WAS) complementary deoxyribonucleic acid (cDNA) into the genome of the patient's hematopoietic stem cells (HSCs). Upon re-infusion, these genetically modified cells engraft in the bone marrow and repopulate the hematopoietic compartment, differentiating into various myeloid and lymphoid lineages—including platelets, T cells, B cells, and natural killer (NK) cells—that express the functional WAS protein (WASP). The restored WASP protein binds to critical signaling partners, such as the Arp2/3 complex and Cdc42, to facilitate actin polymerization. This restoration of cytoskeletal dynamics corrects the structural and functional defects inherent to WAS-deficient cells, such as the inability of T cells to form immunological synapses and the failure of megakaryocytes to release normal-sized platelets.